COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
A Erden, O Karakas, B Armagan, S C Guven, B Ozdemir, E Atalar, H Apaydin, E Usul, I Ates, A Omma, O Kucuksahin
Bratislava Medical Journal, doi:10.4149/bll_2022_018
BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR-positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).
References
Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis, Ann Rheum Dis
Andreoli, Fredi, Nalli, Clinical signifi cance of IgA anticardiolipin and IgA anti-β2glycoprotein I antibodies, Curr Rheumatol Rep
Cavalli, Bramanti, Ciurleo, Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review), Int J Mol Med
Dosquet, Weill, Wautier, Cytokines and thrombosis, J Cardiovasc Pharmacol
Engelmann, Massberg, Thrombosis as an intravascular effector of innate immunity, Nature Rev Immunol
Glass, Subbarao, Murphy, Murphy, Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice, J Immunol
Gralinski, Sheahan, Morrison, Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis, mBio
Han, Yang, Liu, Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clin Chem Lab Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Hunt, A novel antiphospholipid antibody agent?, Blood
Klok, Kruip, Van Der Meer, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res
Li, Lu, Zhang, Clinical observation and management of CO-VID-19 patients, Emerg Microbes Infect
Mckee, Sternberg, Stange, Laufer, Naujokat, Candidate drugs against SARS-CoV-2 and COVID-19, Pharmacol Res
Mekinian, Lazzaroni, Kuzenko, SNFMI and the European Forum on Antiphospholipid Antibodies. The effi cacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study, Autoimmun Rev
Miesbach, Makris, COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation, Clin Appl Thromb Hemost
Miyakis, Lockshi N Md, Atsumi, International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS), J Thromb Haemost
Nalli, Andreoli, Casu, Tincani, Management of recurrent thrombosis in antiphospholipid syndrome, Curr Rheumatol Rep
Pablos, Abasolo, investigators group. Prevalence of hospital PCR-confi rmed COVID-19 cases in patients with chronic infl ammatory and autoimmune rheumatic diseases, Ann Rheum Dis2020
Rheumatism, Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Rodziewicz, Cruz, An update on the management of antiphospholipid syndrome, Ther Adv Musculoskelet Dis
Schmidt-Tanguy, Voswinkel, Henrion, Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients, J Thromb Haemost
Sciascia, Hunt, Talavera-Garcia, Lliso, Khamashta et al., The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies, Am J Obstet Gynecol
So, Mak, So, Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study, Semin Arthritis Rheum
Strangfeld, Schäfer, Gianfrancesco, 19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Taraborelli, Reggia, Dall'ara, Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study, J Rheumatol
Uthman, Gharavi, Viral infections and antiphospholipid antibodies, Semin Arthritis Rheum
Wallace, Gudsoorkar, Weisman, Venuturupalli, New insights into mechanisms of therapeutic effects of antimalarial agents in SLE, Nat Rev Rheumatol
Wilson, Gharavi, Koike, International consensus statement on preliminary classifi cation criteria for defi nite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum
Xiao, Zhang, Zhang, Antiphospholipid Antibodies in Critically Ill Patients With COVID-19, Arthritis Rheumatol
Zhang, Xiao, Zhang, Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19, N Engl J Med
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
